Europe Epigenetics Market
Europe Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Europe epigenetics market is projected to reach USD 1.22 billion by 2030, up from USD 0.63 billion in 2025, registering a CAGR of 14.1% from 2025 to 2030. Growth is supported by a well-funded life sciences ecosystem, with rising oncology and precision medicine programs that increasingly rely on DNA methylation and chromatin profiling for biomarker discovery and translational research.
KEY TAKEAWAYS
-
By CountryThe Germany epigenetics market accounted for a 25.5% revenue share in 2024.
-
By OfferingBy offering, the Europe epigenetics market services segment is expected to register the highest growth rate.
-
By TechnologyBy technology, the Next-generation Sequencing (NGS) segment accounted for the largest market share in 2024.
-
By MethodBy method, the DNA methylation segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive LandscapeCompanies such as Thermo Fisher Scientific, Illumina, and Merck KGaA were identified as some of the key players in the Europe epigenetics market, given their strong market share and product/service footprint.
-
Competitive LandscapeCompanies such as Biomodal and Fios Genomics, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The Europe epigenetics market is experiencing strong growth, driven by rising demand for precise biomarker discovery and multi-omics research supporting oncology, immunology, and precision medicine programs. The increased use of DNA methylation and chromatin profiling workflows across drug discovery and translational studies, supported by well-funded research networks, active biopharma pipelines, and broad adoption across academic institutes, CROs, and clinical research laboratories, is sustaining market momentum across the region.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on stakeholders’ businesses in the European epigenetics market is shaped by the shift toward precision oncology and personalized care, supported by rapid advances in NGS, methylation profiling, chromatin analysis, and multi-omics tools that improve sensitivity, throughput, and data quality. Biopharmaceutical and biotechnology companies, diagnostic laboratories, CROs, and academic and government research institutes are the major users of epigenetics solutions. These products are heavily used across cancer research and drug development, biomarker discovery, patient stratification, therapy, and therapy response monitoring. Growing attention to epigenetic targets, along with the use of epigenetic markers in translational and early clinical workflows, is making epigenetics a central technology in R&D and diagnostics throughout Europe.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Lower sequencing cost and faster turnaround
-
Rising demand for epigenetic-based therapeutics
Level
-
Limited use of epigenomic data in toxicology
Level
-
Emerging applications of epigenetics
-
Integration of epigenetics with multi-omics
Level
-
Technical and validation hurdles in epigenetic editing
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Lower sequencing cost and faster turnaround
Decreasing sequencing costs and improved turnaround times are driving the growth of epigenetic profiling across a variety of research and translational programs throughout Europe; this enables larger cohort studies and more frequent longitudinal sampling without increasing the share of the budget. Shorter time to data also enables quicker decision-making in biomarker discovery and drug development. Consequently, the routine use of methylation and chromatin workflows is being widely adopted in core labs and CROs.
Restraint: Limited use of epigenomic data in toxicology
Epigenomic readouts have not yet been deeply integrated into standard toxicology and safety assessment workflows, which limits their use even in core research applications. Many programs still rely on established endpoints that are more readily accepted by regulators and operationally familiar. This situation reduces short-term demand from preclinical safety teams and, therefore, limits cross-functional engagement within the department. Consequently, the field of epigenetics remains more heavily weighted in the budgets of discovery and translational research.
Opportunity: Emerging applications of epigenetics
Epigenetics remains applicable across various emerging disease types and use scenarios, driven by advances in data availability and analysis capabilities. In addition to cancer, clinical programs in neurology, immunology, and metabolic disease are now exploring the utility of epigenetics for stratification and monitoring. This broadens the addressable market, thereby facilitating demand for emerging kits, services, and software. In addition, there are opportunities for differentiated solutions tailored to specific use scenarios.
Challenge: Technical and validation hurdles in epigenetic editing
Epigenetic editing is still affected by the complexity of the technique, including delivery limitations, potential off-target effects, and the need for validation, especially in the transition from proof of concept to a more translational or therapeutic environment. These constraints lead to longer development times and increased expenditure in building a strong body of evidence. As a result, current use is found mostly in research labs.
EUROPE EPIGENETICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
AstraZeneca profiled osimertinib drug-tolerant persister lung cancer models using ATAC-seq and RNA-seq. The team paired this with drug screens to identify actionable vulnerabilities and guide combination hypotheses. | Improves understanding of resistance biology. Supports faster target prioritization and more rational combination selection. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The European epigenetics market ecosystem includes consumables suppliers for DNA methylation and chromatin ion workflows, along with sequencing, single-cell, and automation vendors that facilitate sample-to-data processing. It further encompasses bioinformatics and software providers that enable epigenomic pipelines, multi-omics integration, and compliant data environments for large, multi-country datasets. CROs, contract labs, and academic facilities support profiling, assay development, and large-scale interpretation. The major end users are biopharma and biotech companies, universities and public research institutes, and hospitals and diagnostic labs, which implement these technologies across precision oncology, biomarker-driven drug development, and novel methylation-based translational and early clinical testing.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Europe epigenetics market, By Offering
In 2024, kits and reagents dominated the European epigenetics market because epigenetics workflows are highly consumable-driven, requiring repeated purchases of bisulfite conversion kits, methylation library prep kits, antibodies, and chromatin assay reagents. These products scale directly with sample volumes across academic institutions, CROs, and biopharma R&D programs. Ready-to-use kits are also preferred because they improve reproducibility across multi-site European studies and reduce protocol-to-protocol variability.
Europe epigenetics market, By Technology
In 2024, NGS dominated Europe epigenetics market by delivering high-throughput, information-rich profiling of methylation sequencing and chromatin readouts at scale. Europe’s strong base of genomics centers and consortium-led programs favors sequencing-based approaches for large cohorts and longitudinal studies. Established sequencing infrastructure and improving cost efficiency further reinforce NGS adoption in both discovery and translational epigenomics.
Europe epigenetics product market, By Application
In 2024, oncology dominated the Europe epigenetics market, as epigenetic alterations are central to tumor biology, disease classification, and biomarker discovery. Methylation and chromatin signatures are widely used to support patient stratification, treatment response assessment, and resistance research in translational studies. The growing pipeline of targeted therapies and expanding liquid biopsy research in European clinical networks continue to make oncology the primary demand driver.
REGION
Germany to be the fastest-growing country in the Europe Epigenetics market during the forecast period
In 2024, Germany was the fastest growing country in the Europe epigenetics market, supported by its strong pharma and biotech industry and presence of a large number of academic universities, research institutes, and hospitals conducting high-throughput epigenomics programs. The country’s developed genomics infrastructure and well-established facilities are accelerating the adoption of NGS-based epigenetic profiling and downstream analytics.
EUROPE EPIGENETICS MARKET: COMPANY EVALUATION MATRIX
In the Europe epigenetics market matrix, Thermo Fisher Scientific Inc. (Star) leads with its broad, end-to-end portfolio supporting methylation and chromatin workflows, backed by strong distribution reach and deep penetration across European academic institutes, CROs, and biopharma R&D sites. F. Hoffmann-La Roche Ltd. (Emerging Leader) is building momentum through its growing role in translational and clinical epigenetics, leveraging strengths in diagnostics and oncology programs where methylation and multi-omics insights support biomarker development and patient stratification.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific, Inc. (US)
- Merck KGaA (Germany)
- Illumina, Inc. (US)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fios Genomics (UK)
- GenomeScan (Netherlands)
- Biomodal (UK)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 0.57 Billion |
| Market Forecast in 2030 (Value) | USD 1.22 Billion |
| Growth Rate | CAGR of 14.1% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | Germany, UK, France, Italy, Spain, Rest of Europe |
WHAT IS IN IT FOR YOU: EUROPE EPIGENETICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| UK competitive landscape |
|
|
| NORDIC growth opportunity |
|
|
RECENT DEVELOPMENTS
- April 2025 : QIAGEN launched QIAseq Multimodal Cancer Genomics Panels, designed to advance cancer genomic profiling by enabling comprehensive analysis of key biomarkers across DNA and RNA, supporting applications such as targeted oncology research, biomarker discovery, and translational medicine.
- May 2024 : QIAGEN launched the QIAseq Multimodal DNA/RNA Library Kit, enabling seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS).
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research involved extensively using secondary sources, directories, and databases to gather valuable information for analyzing the global Europe Epigenetics Market. In-depth interviews were conducted with various key respondents, including industry leaders, subject-matter experts (SMEs), C-level executives of major market players, and industry consultants, to obtain and verify critical qualitative and quantitative data and to evaluate the market's growth prospects. The global market size, estimated through secondary research, was then triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the Europe Epigenetics Market. The secondary sources used for this study include World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Union of Biochmistry and Molecular Biology (IUBMB), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), Canadian Society for Molecular Biosciences (CSMB), National Institute of Environmental Health Sciences (NIEHS), Canadian Institutes of Health Research (CIHR), Genome Canada, and Central Drugs Standard Control Organisation (CDSCO); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global Europe Epigenetics Market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Europe Epigenetics Market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown procedures were used whenever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
Market Definition
Epigenetics involves assessing individual behaviors and environmental factors that may influence gene functions. Unlike genetic changes, epigenetic modifications can be reversed and do not alter the DNA sequence. The report provides both qualitative and quantitative analyses of various products and services used in epigenetics research by end users such as academic and research institutions, pharmaceutical and biotechnology companies, and hospitals and clinics.
Stakeholders
- Contract research organizations (CROs)
- Contract development and manufacturing organizations (CDMOs)
- Pharmaceutical & biopharmaceutical companies
- Life science companies
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the Europe Epigenetics Market by offering, method, technology, application, end user (product), end user (service), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall Europe Epigenetics Market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as product launches, agreements, partnerships, acquisitions, and R&D activities
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the Europe Epigenetics Market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Europe Epigenetics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Europe Epigenetics Market